Mariana Oncology

Mariana Oncology is a private, preclinical-stage biotech subsidiary of Novartis, focused on developing targeted radioligand therapies (RLTs) for cancer. Its pipeline includes lead programs against DLL3 and B7-H3, targets associated with aggressive, hard-to-treat cancers with poor prognoses. The company leverages Novartis's expertise in the RLT field to design compounds for selective tumor targeting and rapid clearance, aiming to establish a new standard of care. As a fully integrated part of Novartis, it operates with strategic backing but faces competition in the rapidly evolving radiopharmaceutical sector.

Platform for designing precision radioligand therapies, focusing on novel target selection, ligand engineering for selective binding and tumor penetration, and optimization of pharmacokinetics for rapid clearance to maximize therapeutic index.

The radioligand therapy field is highly competitive, with Novartis (parent), Bayer, and recently consolidated players like Bristol Myers Squibb (RayzeBio) and AstraZeneca (Fusion Pharmaceuticals) as major contenders. Competition is fierce for novel targets, radioisotope supply, and technological innovation.